Suppr超能文献

原发性高血压中的转换酶抑制作用:降压反应并非仅反映血管紧张素II生成减少。

Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.

作者信息

Swartz S L, Williams G H, Hollenberg N K, Moore T J, Dluhy R G

出版信息

Hypertension. 1979 Mar-Apr;1(2):106-11. doi: 10.1161/01.hyp.1.2.106.

Abstract

To determine the relative importance of hormonal factors in mediating the hypotensive response to converting enzyme inhibition (CEI), plasma renin activity (PRA), angiotensin II, and bradykinin responses to SQ20,881 were measured in 20 supine patients with essential hypertension in balance on a 10 mEq sodium diet. Patients were divided into two groups according to their diastolic blood pressure response: responders had a decrement in diastolic pressure which exceeded 9 mm Hg, the upper value of the 95% confidence limits for normotensive patients studied under similar conditions; nonresponders did not. Compared to the nonresponders, responders not only had a higher control PRA (8.7 +/- 1.7 ng/ml/hr vs 4.8 +/- 2.1, p < 0.05) and larger decrement in plasma angiotensin II (18.7 +/- 4.9 pg/ml vs 3.2 +/- 1.7, p < 0.01), but also had a higher control bradykinin (3.2 +/- 0.7 ng/ml vs 1.1 +/- 0.2, p < 0.05) and larger increment in bradykinin (4.5 +/- 1.3 ng/ml vs 1.0 +/- 0.4, p < 0.05) following SQ20,881. Because SQ20,881 altered both angiotensin II and bradykinin concentrations, we assessed the contribution of blockade of angiotensin II formation by administering angiotensin II infusions to seven responders during coverting enzyme blockade, with the angiotensin II dose adjusted to restore diastolic pressure to control levels. The plasma angiotensin II level required to return blood pressure to control was 45 +/- 15 pg/ml higher than the control plasma angiotensin II level (p < 0.01), suggesting that some other factor(s), perhaps bradykinin, are also responsible for the hypotensive response to converting enzyme inhibition.

摘要

为了确定激素因素在介导对转换酶抑制(CEI)的降压反应中的相对重要性,我们对20例仰卧位原发性高血压患者进行了研究,这些患者在10 mEq钠饮食条件下保持平衡。测量了他们的血浆肾素活性(PRA)、血管紧张素II以及对SQ20,881的缓激肽反应。根据舒张压反应将患者分为两组:反应者的舒张压下降超过9 mmHg,这是在类似条件下研究的正常血压患者95%置信区间的上限值;无反应者则未达到此标准。与无反应者相比,反应者不仅基础PRA较高(8.7±1.7 ng/ml/hr对4.8±2.1,p<0.05),血浆血管紧张素II下降幅度更大(18.7±4.9 pg/ml对3.2±1.7,p<0.01),而且基础缓激肽水平也较高(3.2±0.7 ng/ml对1.1±0.2,p<0.05),注射SQ20,881后缓激肽增加幅度更大(4.5±1.3 ng/ml对1.0±0.4,p<0.05)。由于SQ20,881同时改变了血管紧张素II和缓激肽的浓度,我们通过在转换酶阻断期间对7例反应者输注血管紧张素II来评估血管紧张素II形成受阻的作用,调整血管紧张素II的剂量以将舒张压恢复到对照水平。使血压恢复到对照水平所需的血浆血管紧张素II水平比对照血浆血管紧张素II水平高45±15 pg/ml(p<0.01),这表明其他一些因素,可能是缓激肽,也参与了对转换酶抑制的降压反应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验